BCDA · BioCardia, Inc.
AI read · Bad for BCDA
The AI's read
BioCardia filed an 8-K showing it received a notice of delisting for failing to meet continued listing standards. For a microcap biotech that typically triggers liquidity loss and financing stress. Price is up about 1.3% since the filing and RSI sits near 52, so the market hasn't panicked or repriced aggressively. That said, market cap is tiny and a transfer to OTC would likely compress value sharply. We lean bearish because delisting narrows exit routes and magnifies downside for small bios. Conviction 84 given the clear regulatory notice and immediate timing.